Versions
- 2022-01-28 (3)
- 2022-01-28 (2)
- 2022-01-27 (1)
Keywords
prevalence
Costa Rica
How to Cite
Abstract
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease that has a national reference center in Costa Rica. Based on the promulgation of Executive Decree 28838-H of July 17, 2000, the National Center for Pain Control and Palliative Care became the reference center for all patients with ALS, in order to improve quality of life of patients and families facing this disease. The objective of this study was to know the prevalence and other epidemiological variables of ALS in Costa Rica in the first semester of 2014. Methods: the data collection was made from the reports generated by the Integrated Health Information System. The database with the variables of sex, age and domicile of each patient was elaborated. Simple frequencies were performed and the prevalence was estimated for 2014, at the National Center for Pain Control and Palliative Care. Results: the population was 129 patients with an average age of 60 years. The gender distribution was 63% men and 37% women. A prevalence of 3.00 cases per 100,000 of the total population (95% CI, 2.48-3.52) was found. The study shows that the prevalence of patients with ALS is higher in the central valley. Conclusion: the prevalence of ALS in Costa Rica is within the expected worldwide, being more frequent in males.
References
Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, et al. Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis. Arch Ital Biol. 2011;149:151-67. doi: 10.4449/aib.v149i1.1267
Mitsumoto H, Hanson MR, Chad DA. Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials. Arch Neurol. 1988;45(2):189-202. doi: 10.1001/archneur.1988.00520260077025.
Fallas Sanabria M. Esclerosis Lateral Amiotrófica. Rev Med Costa Rica Centroam [Internet]. 2010;67(591):89-92. Disponible en: https://www.medigraphic.com/pdfs/revmedcoscen/rmc-2010/rmc10591r.pdf
Houseman G. Symptom Management of the Patient with Amyotrophic Lateral Sclerosis. J Hosp Palliat Nurs. 2008;10(4):207-213. doi: 10.1097/01.NJH.0000319165.20349.e8
Lomen-Hoerth C. Amyotrophic lateral sclerosis from bench to bedside. Semin Neurol. 2008;28(2):205-11. doi: 10.1055/s-2008-1062265.
Howard RS, Orrell RW. Management of motor neurone disease. Postgrad Med J. 2002;78(926):736-41. doi: 10.1136/pmj.78.926.736.
Marín Prida J. Esclerosis lateral amiotrófica: una actualización. Rev Mex Neuroci [Internet]. 2009;10(4):281-286. Disponible en: https://www.medigraphic.com/pdfs/revmexneu/rmn-2009/rmn094g.pdf
Martí-Fabregas J, Pradas J. Esclerosis lateral amiotrófica. Neurología. 1996;11(3):99-103.
Borasio GD. Esclerosis lateral amiotrófica. En: Walsh D, editor. Medicina Paliativa. Barcelona: Elsevier; 2010. 1062-1067.
Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-9. doi: 10.1080/146608200300079536.
Morales Alpízar C, Saint-Hillaire Arce C. Demandas de pacientes y familiares que se presentaron fuera del horario diurno del Centro Nacional de Control del Dolor y Cuidados Paliativos en octubre y noviembre del 2004 [Tesis de Maestría en Administración de Servicios de Salud Sostenibles]. San José: UNED 2006. Disponible en: https://core.ac.uk/download/pdf/67708287.pdf
Chió A, Terreni A, Cucatto A, Calvo A, Bertolotto A, Bottacchi E, et al. Incidence of ALS in Italy: Evidence for a uniform frequency in Western countries. Neurology. 20014;56(2):239-244.
Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Suppl [Internet]. 2014;63(7):1-14. Disponible en: https://www.cdc.gov/mmwr/pdf/ss/ss6307.pdf
Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology. 1999;52(3):504-9. doi: 10.1212/wnl.52.3.504.
Piemonte and Valle d'Aosta Register for Amyotrophic Lateral Sclerosis. Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology. 2001;56(2):239-44. doi: 10.1212/wnl.56.2.239.
Rodríguez-Paniagua P, Salas-Herrera I, Cartín-Brenes M. Incidencia de esclerosis lateral amiotrófica en Costa Rica. Acta Méd Costarric [Internet]. 2007;49:33-37. Disponible en: https://www.scielo.sa.cr/pdf/amc/v49n1/3306.pdf
Vásquez Espinar M, Eimil Ortiz M, Arroyo González R. Esclerosis lateral amiotrófica: pronóstico y tratamiento. JANO [internet]. 2005;1579:49-53. Disponible en: https://1library.co/document/y8x4g1rq-esclerosis-lateral-amiotrofica-pronostico-y-tratamiento.html
Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci. 1999;169(1-2):2-12. doi: 10.1016/s0022-510x(99)00209-9.
Instituto Nacional de Estadística y Censos (CR). X Censo Nacional de Población y VI de Vivienda 2011: Resultados Generales [Internet]. San José: INEC; 2012. Disponible en: https://www.inec.cr/sites/default/files/documentos/inec_institucional/estadisticas/resultados/repoblaccenso2011-15.pdf.pdf
Caja Costarricense de Seguro Social. Reglamento del Seguro de Invalidez Vejez y Muerte de la Caja Costarricense de Seguro Social. San José: CCSS; 1995. Disponible en: https://oig.cepal.org/sites/default/files/costa_rica_-_reglamento_sivm.pdf
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2022 Grethel Carolina Alfaro Campos, Daniel Ulate-Gómez